Table 2.

Patient response and GIN prediction of outcome (N = 18)a

Patient IDDiagnosisImmunotherapyPFSb (months)OutcomeGIN PredictioncComments
1Basal cell carcinomaNivolumab18.43+Response (PR)Response
30Head and neck SCCPembrolizumab5.9ProgressionProgressionSee Fig. 4
40Cutaneous SCCPembrolizumab13.40+Response (CR)ResponseSee Fig. 4
40BBladder urothelial carcinomaAtezolizumab + SBRT1.8ProgressionProgressionHyperprogression; see Fig. 4
51Ocular melanomaNivolumab/ipilimumab12.0Response (SD 12 months)Response
55MelanomaNivolumab/ipilimumab10.03+Response (CR)Response
65Colorectal adenocarcinomaNivolumab + SBRT2.3ProgressionProgression
67NSCLC SCCNivolumab + SBRT1.7ProgressionProgression
69NSCLC adenocarcinomaPembrolizumab4.1ProgressionProgression
70Basal cell carcinomaPembrolizumab2.5ProgressionProgression
79Endometrial sarcomaNivolumab + vismodegib + trametinib + anastrozole1.9ProgressionProgression
82Thyroid cancerPembrolizumab1.9ProgressionProgression
83Ovarian cancerNivolumab + SBRT0.9ProgressionProgression
100Neuroendocrine carcinoma of unknown primaryNivolumab + trametinib2.2ProgressionProgression
110Esophageal cancerNivolumab4.0ProgressionResponseSee Supplementary Fig. S4
111Breast cancerPembrolizumab5.5Progression (after 5.5 months of SD)SDMinimal change in GIN noted at day +43
114NSCLC SCCNivolumab5.1Response (PR)Response
125GE junction adenocarcinomaPembrolizumab + SBRT2.0+Response (PR)ResponsePseudoprogression; see Fig. 4
  • Abbreviations: GE junction, gastroesophageal junction; ID, identification number; NSCLC, non–small cell lung cancer; SBRT, stereotactic body radiation therapy; SCC, squamous cell cancer.

  • aPatients with SD ≤ 9 months and PD are considered progressors; patients with SD > 9 months/PR/CR are considered responders.

  • bPFS values with a (+) indicate response is ongoing at time of data censoring. Data for GIN prediction taken from day +42 or the nearest time point thereafter.

  • cPatient 110 showed a clonal response by GIN, but achieved only short-lived (4 month) SD (Supplementary Fig. S5); hence, in this patient, the GIN prediction of response was considered discrepant with the RECIST findings and our classification of this individual as a progressor. Patient 111 showed only a marginal change at day +43, and GIN could therefore not be used to predict either response or progression; the patient had SD that lasted 5.5 months, and then the tumor progressed. For Patient 83, data from day +21 were used for GIN prediction due to a change in therapy to chemotherapy soon after that date.